logo

Stock Screener

Forex Screener

Crypto Screener

DHR

Danaher Corporation (DHR)

$

219.62

-4.92 (-2.24%)


Key metrics

Financial statements

Free cash flow per share

Free cash flow per share

7.4367

Market cap

Market cap

155.2 Billion

Price to sales ratio

Price to sales ratio

6.3192

Debt to equity

Debt to equity

0.3506

Current ratio

Current ratio

1.8740

Income quality

Income quality

1.7753

Average inventory

Average inventory

2.6 Billion

ROE

ROE

0.0699



Technology

Technology

Technology – consumer electronics

Largecap

Largecap

With a market cap of 121,78 bil stock is ranked 1

Low risk

Low risk

ISS score of this stock is ranked 1


Company description

Profile

Danaher Corporation designs, manufactures, and markets a wide array of professional, medical, industrial, and commercial products and services on a global scale. The company operates through three primary segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides an extensive range of products, including mass spectrometers, flow cytometry solutions, genomics instruments, lab automation systems, centrifugation devices, particle counting and characterization tools, and microscopes. This segment is also engaged in genomics consumables and Gene and Cell Therapy, in addition to offering bioprocess technologies, consumables, and services. Furthermore, it supplies filtration, separation, and purification technologies catering to pharmaceutical and biopharmaceutical companies, as well as food and beverage firms, medical institutions, universities, and various industrial manufacturers. The Diagnostics segment delivers a comprehensive suite of diagnostic solutions, which includes chemistry, immunoassay, microbiology, and automation systems alongside an array of hematology, molecular, acute care, and pathology diagnostics products. This segment also encompasses clinical instruments, reagents, consumables, software, and services that are essential for hospitals, physicians’ offices, reference laboratories, and other critical care environments. Meanwhile, the Environmental & Applied Solutions segment focuses on providing instrumentation, consumables, software, services, and disinfection systems designed to analyze, treat, and manage various types of water across residential, commercial, industrial, and natural resource applications. Moreover, it offers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality management, as well as printing, marking, coding, and traceability applications across consumer, pharmaceutical, and industrial sectors. The company, originally known as Diversified Mortgage Investors, Inc., rebranded as Danaher Corporation in 1984. Established in 1969, the company is headquartered in Washington, D.C. The income before tax ratio is 0.17 reflecting the pre-tax margin. The company reported a substantial revenue of $24,568,000,000.00 reflecting its strong market presence. The EBITDA is $7,019,000,000.00 a key indicator of the company's operational profitability. The company reported an income before tax of $4,233,000,000.00 showcasing its pre-tax profitability. Additionally, the company reported selling, general, and administrative expenses of $8,235,000,000.00 indicating its operational overhead costs. Danaher Corporation’s stock is priced at $193.29 positioning it in the higher-end market. The stock has a high average trading volume of 3,512,513.00 indicating strong liquidity. With a large market capitalization of $155,249,378,000.00 the company is a dominant player. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth.

What is Danaher Corporation (DHR)'s current stock price?

The current stock price of Danaher Corporation (DHR) is $220.28 as of 2026-01-30. Prices may fluctuate during the trading day. For real-time updates, check your brokerage platform or financial news websites.

Investing in Danaher Corporation (DHR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.

Analysts predict Danaher Corporation stock to fluctuate between $171 (low) and $242.80 (high) in the next 365 days, reflecting market expectations and potential volatility.

As of 2026-01-30, Danaher Corporation's market cap is $155,249,378,000, based on 706,900,000 outstanding shares.

Compared to Eli Lilly & Co., Danaher Corporation has a Lower Market-Cap, indicating a difference in performance.

Danaher Corporation pays dividends. The current dividend yield is 0.56%, with a payout of $0.32 per share.

To buy Danaher Corporation (DHR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DHR. Place an order (Market, Limit, etc.).

The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.

Danaher Corporation's last stock split was 141:125 on 2023-10-02.

Revenue: $24,568,000,000 | EPS: $5.07 | Growth: -4.88%.

Visit https://www.danaher.com/investor-relations for detailed financial reports.

You can explore historical data from here

All-time high: $333.96 (2021-09-10) | All-time low: $171 (2025-04-09).

Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.


News

DHR

zacks.com

Danaher Q4 Earnings Beat Estimates, Life Sciences Sales Up Y/Y

DHR beats Q4 estimates as sales rise 4.5%, driven by strength across Life Sciences, Diagnostics and Biotech, and issued upbeat 2026 earnings guidance.

DHR

seekingalpha.com

Danaher Corporation (DHR) Q4 2025 Earnings Call Transcript

Danaher Corporation (DHR) Q4 2025 Earnings Call Transcript

DHR

zacks.com

Compared to Estimates, Danaher (DHR) Q4 Earnings: A Look at Key Metrics

The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

DHR

zacks.com

Danaher (DHR) Beats Q4 Earnings and Revenue Estimates

Danaher (DHR) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.14 per share a year ago.

DHR

reuters.com

Danaher forecasts 2026 profit in line with estimates on pharma spending recovery

Life sciences firm Danaher Corp forecast annual profit largely in line with Wall Street estimates on Wednesday and beat fourth-quarter profit and revenue expectations, as improving conditions in the pharmaceutical market and reduced policy uncertainties offset weakness in academic research funding.

DHR

prnewswire.com

Danaher Reports Fourth Quarter and Full Year 2025 Results

WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025.  All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

DHR

zacks.com

Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?

DHR is set to report Q4 results on Jan. 28, with revenues seen up 3.9% and bioprocessing and diagnostics strength in focus.

DHR

zacks.com

Danaher (DHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DHR

seekingalpha.com

Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

DHR

seekingalpha.com

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

Mar Vista's U.S. Quality strategy returned +0.20% net-of-fees in Q4 2025. The Russell 1000 Index and the S&P 500 Index returned +2.41% and +2.65%, respectively. Alphabet, Johnson & Johnson and Danaher Corp. were among the portfolio's top contributors for the quarter.

See all news

logo
Stocks, Indicators, Pattern screeners all at one place
Stock Screener
Forex Screener
Crypto Screener